The World EPA organisers have curated an exceptional programme featuring thought-provoking presentations and dynamic panel ...

That’s the conclusion of hiring managers at four of the state’s leading life sciences companies who spoke at a recent career ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the ...

Versant Ventures has made its fourth investment in an obesity startup in eight months, co-leading a $65 million Series A round in Helicore Biopharma, a developer of an antibody drug that blocks a gut ...

Sage Ther­a­peu­tics knows it needs to do some­thing. But it doesn’t want to sell to its part­ner Bio­gen.

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Ei­sai and Bio­gen scored an ap­proval for once-month­ly IV main­te­nance dos­ing of their Alzheimer’s drug Leqem­bi, as part of what they’ve said is an on­go­ing … ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

Deadbeat drivers racked up $5.1 billion in unpaid MTA tolls and violations over four years — a number likely sent skyrocketing since “cashless” systems replaced the old payment booths ...